{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05921266",
            "orgStudyIdInfo": {
                "id": "UA15561"
            },
            "organization": {
                "fullName": "University of Oklahoma",
                "class": "OTHER"
            },
            "briefTitle": "Urolithin A Supplementation in Middle-aged Adults With Obesity",
            "officialTitle": "Urolithin A Supplementation to Improve Endothelial and Cerebrovascular Function in Middle-aged Adults With Obesity",
            "therapeuticArea": [
                "Other",
                "Endocrinology",
                "Neurology"
            ],
            "study": "urolithin-a-supplementation-in-middle-aged-adults-with-obesity"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-12",
            "studyFirstSubmitQcDate": "2023-06-26",
            "studyFirstPostDateStruct": {
                "date": "2023-06-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Oklahoma",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is:\n\n- Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity?\n\nParticipants will be asked to:\n\n* Take the dietary supplement daily for 4 weeks\n* Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood\n\nResearchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.",
            "detailedDescription": "This study aims to measure the effect of urolithin A supplementation on endothelial function, cerebral blood flow regulation, and serum biomarkers of NO bioavailability and mitochondrial function in middle-aged adults with obesity. Briefly, 54 adults aged 40-64 years of age with a body mass index equal to or greater than 30 kg/m2 will be recruited to participate in a double-blind placebo-controlled parallel study for 4 weeks. Participants will be randomly assigned to intervention or control group. Those in the intervention group will consume 1,000 mg of urolithin A daily in the form of softgel capsules, whereas those in the control group will consume a placebo. Data collection will occur at baseline (day 0) and endpoint (day 28). The investigators will compare outcomes between control and intervention group. Researchers expect that urolithin A supplementation in middle-aged adults with obesity improves endothelial function and cerebral blood flow regulation, and that this improvement is accompanied by changes in biomarkers of NO bioavailability and mitochondrial function."
        },
        "conditionsModule": {
            "conditions": [
                "Obesity",
                "Vascular Dementia",
                "Cognitive Impairment"
            ],
            "keywords": [
                "Obesity",
                "Urolithin A",
                "Middle aged",
                "Flow-mediated dilation",
                "Endothelial function",
                "fNIRS",
                "Nitric oxide",
                "Vascular contributions to cognitive impairment and dementia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 54,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intervention",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Dietary Supplement: Urolithin A"
                    ]
                },
                {
                    "label": "Control",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "Urolithin A",
                    "description": "Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).",
                    "armGroupLabels": [
                        "Intervention"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).",
                    "armGroupLabels": [
                        "Control"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in arterial function and local stiffness",
                    "description": "Flow-mediated dilation",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in blood flow on the surface of the hand",
                    "description": "Laser speckle contrast imaging",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Change in homeostatic cerebral blood flow",
                    "description": "Functional near-infrared spectroscopy",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Change in plasma biomarkers of NO homeostasis",
                    "description": "Asymmetrical dimethylarginine",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Change in plasma biomarkers of NO homeostasis",
                    "description": "Endothelin-1",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Change in plasma biomarkers of NO homeostasis",
                    "description": "Bioactive nitrogen oxides",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Change in plasma biomarkers of mitochondrial function",
                    "description": "Acylcarnitines",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Body weight",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Body fat percentage",
                    "description": "Bioelectric impedance",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                },
                {
                    "measure": "Waist circumference",
                    "timeFrame": "Baseline (day 0) and endpoint (day 28)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 40-64 years old, inclusive\n* Obesity \\[BMI \u226530 kg/m2\\]\n* Ability to read, write, and speak English\n* Competence to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women who intend to become pregnant within the study period\n* History of hypertension\n* History of type 1 or type 2 diabetes mellitus\n* Significant cardiac disease or chest pain in the last 6 months\n* History of depression or anxiety\n* History of cognitive impairment\n* History of significant GI disease (e.g., IBS, Crohn's disease)\n* Allergy or intolerance to one or more of the intervention components\n* Undergoing treatment for active cancer\n* History of neurodegenerative disorders (e.g., multiple sclerosis)\n* Presence of any condition affecting swallowing ability\n* Any other medical condition that the investigators deem would adversely affect the participant's safety or ability to complete the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "maximumAge": "64 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Andriy Yabluchanskiy, MD, PhD",
                    "role": "CONTACT",
                    "phone": "405-271-8000",
                    "email": "andriy-yabluchanskiy@ouhsc.edu"
                },
                {
                    "name": "Ana Clara da Costa Pinaffi Langley, MSc, ELS",
                    "role": "CONTACT",
                    "phone": "405-271-8001",
                    "email": "anaclara-dacostapinaffilangley@ouhsc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andriy Yabluchanskiy, MD, PhD",
                    "affiliation": "University of Oklahoma Health Science Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Translational GeroScience Laboratory - O'Donoghue Research Building",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73117",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andriy Yabluchanskiy, MD, PhD",
                            "role": "CONTACT",
                            "phone": "405-271-8130",
                            "email": "gerolab@ouhsc.edu"
                        },
                        {
                            "name": "Andriy Yabluchanskiy, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ana Clara da Costa Pinaffi Langley, MSc, ELS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Camila Bonin Pinto, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "ICF"
            ],
            "timeFrame": "Starting 6 months after publication",
            "accessCriteria": "By request upon PI approval"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000015140",
                    "term": "Dementia, Vascular"
                },
                {
                    "id": "D000009765",
                    "term": "Obesity"
                },
                {
                    "id": "D000060825",
                    "term": "Cognitive Dysfunction"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000003072",
                    "term": "Cognition Disorders"
                },
                {
                    "id": "D000002561",
                    "term": "Cerebrovascular Disorders"
                },
                {
                    "id": "D000002537",
                    "term": "Intracranial Arteriosclerosis"
                },
                {
                    "id": "D000020765",
                    "term": "Intracranial Arterial Diseases"
                },
                {
                    "id": "D000056784",
                    "term": "Leukoencephalopathies"
                },
                {
                    "id": "D000001161",
                    "term": "Arteriosclerosis"
                },
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29705",
                    "name": "Cognitive Dysfunction",
                    "asFound": "Cognitive Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "asFound": "Dementia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7292",
                    "name": "Dilatation, Pathologic",
                    "relevance": "LOW"
                },
                {
                    "id": "M17861",
                    "name": "Dementia, Vascular",
                    "asFound": "Vascular Dementia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6301",
                    "name": "Cognition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5810",
                    "name": "Cerebrovascular Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4469",
                    "name": "Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M5786",
                    "name": "Intracranial Arteriosclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M22521",
                    "name": "Intracranial Arterial Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M28591",
                    "name": "Leukoencephalopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12507",
                    "name": "Nitric Oxide",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}